Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).
Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resistance, and what the future holds for these patients.
Tony Mok, MD, of The Chinese University of Hong Kong, and Alice Shaw, MD, PhD, of Massachusetts General Hospital, discuss the current status and future outlook of ALK inhibition, and an assessment of brigatinib CNS activity in patients with ALK-positive non-small cell lung cancer and intracranial metastases (Abstract 3061).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, summarizes his educational lecture on obesity, inflammation, and cancer—an important topic in oncology.
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.
Frederic Amant, MD, PhD, of the Katholieke Universiteit Leuven, discusses the important decisions that must be made when a woman is diagnosed with cancer while pregnant: Should treatment be delayed or the pregnancy terminated?
